

Oncomine World 2023 event program

March 30, 2023

To accommodate our global audience, presentations will be held over a 24-hour period in three live sessions. Please consult this program for talks in your time zone.

In addition to the presentations below, enjoy access to on-demand content from past OncomineWorld meetings, visit virtual laboratories to learn about applications of next-generation sequencing (NGS) in precision oncology research, and explore interactive and educational features.

Asia Pacific live session: 12:00–14:35 SGT

Welcome:

Luca Quagliata, PhD, MCMAS, COA, Vice President and Global Head of Medical Affairs, Thermo Fisher Scientific, **12:00–12:05 SGT**

Part 1: General education

Concordance of targeted sequencing from circulating tumor DNA and paired tumor tissue: Dr. Chi-Cheng Huang, Director of Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taiwan, **12:05–12:25 SGT**

Clinical utility of NGS in liquid biopsy for lung cancer:

Dr. Anuradha Chougule, Consultant, Medical Oncology, Tata Memorial Hospital, Mumbai, India; Chair Professor (CoE), Cancer Research in Genetics, Maharashtra University of Health Sciences (MUHS), Maharashtra, India, **12:25–12:50 SGT**

Q&A: 12:50–13:00 SGT

Part 2: Oncomine Clinical Research Grant awardee presentations

TCR repertoire profiling to predict NSCLC response to immunotherapy—feasibility study: Elin Gray, BSc, MSc, PhD, Associate Professor, Edith Cowan University, Australia, **13:00–13:15 SGT**

Q&A: 13:15–13:20 SGT

Break: 13:20–13:35 SGT

Part 3: Clinical oncology research

Genomic instability metric (GIM) for HRD assessment:

Elaine Wong-Ho, PhD, Sr. Product Manager, Oncology, Thermo Fisher Scientific, **13:35–13:50 SGT**

Evaluation of the Oncomine™ Comprehensive Assay v3 and early experience with the Oncomine Comprehensive Assay Plus on the Genexus™ System: Dr. Bin Wang, Senior Hospital Scientist, SydPath—St. Vincent's Hospital, Sydney, Australia, **13:50–14:10 SGT**

Q&A: 14:10–14:20 SGT

Genexus System demonstration with live Q&A: Andrew Hutchison, Director, Instruments, Thermo Fisher Scientific, **14:20–14:35 SGT**

Europe and the Americas live session: 15:00–18:10 CET

Welcome:

Luca Quagliata, PhD, MCMAS, COA, Vice President and Global Head of Medical Affairs, Thermo Fisher Scientific, **15:00–15:05 CET**

Part 1: Clinical research

Genomic instability metric (GIM) for HRD assessment:

Elaine Wong-Ho, PhD, Sr. Product Manager, Oncology, Thermo Fisher Scientific, **15:05–15:15 CET**

Oncomine Comprehensive Assay Plus - Genomic Instability

Metric (GIM): Annette Staebler, MD, Head of Gynecological Pathology and Mammary Pathology Division, University Hospital Tuebingen, Germany, **15:15–15:45 CET**

Q&A: 15:45–15:55 CET

Simultaneous DNA and RNA variant testing by Oncomine™

Precision Assay: Annarita Destro, PhD, Head of Molecular Pathology Department, Humanitas Research Hospital, Italy, **15:55–16:05 CET**

Q&A: 16:05–16:10 CET

Break: 16:10–16:25 CET

Part 2: Oncomine Clinical Research Grant awardee presentations

Feasibility of rapid lung NGS testing: Fernando López-Ríos, MD, PhD, Department of Pathology, University Hospital October 12, Madrid, Spain, **16:25–16:40 CET**

Q&A: 16:40 - 16:45 CET

Part 3: Clinical patient testing

Ion Torrent™ Oncomine™ Dx Express Test—Multiple sites evaluation results and routine experience: Paul Hofman MD, PhD, Professor of Pathology and Head of Laboratory of Clinical and Experimental Pathology at Louis Pasteur Hospital, Nice, France, **16:45–17:05 CET**

Q&A: 17:05–17:10 CET

Part 4: General education

Molecular analysis in the diagnosis and prognosis of haematological malignancies: Dr. Geetha Menon, MD, Clinical Director, Lihui Wang, PhD, Lead; Haemato-oncology Diagnostic Service (HODS) Cheshire & Merseyside Cancer Network, Liverpool Clinical Laboratories, United Kingdom, **17:10–17:50 CET**

Q&A: 17:50–17:55 CET

Part 4: Clinical research

Genexus System demonstration with live Q&A: Andrew Hutchison, Director, Instruments, Thermo Fisher Scientific, **17:55–18:10 CET**

Americas live session: 12:00–14:55 PT

Welcome:

Luca Quagliata, PhD, MCMAS, COA, Vice President and Global Head of Medical Affairs, Thermo Fisher Scientific, **12:00–12:05 PT**

Part 1: General education

Rapid tissue-based molecular testing in oncology: Lauren Ritterhouse, MD, PhD, Associate Director for the Center of Integrated Diagnostics, Massachusetts General Hospital, Boston, Massachusetts, Assistant Professor of Pathology, Harvard Medical School **12:05–12:25 PT**

Clinical utility of amplicon-based comprehensive genomic profiling (CGP): Eric Vail, MD, Director of Molecular Pathology, Cedars-Sinai Medical Center, Los Angeles, California, **12:25–12:55 PT**

Q&A: 12:55–13:05 PT

Break: 13:05–13:20 PT

Clinical impact of front-line NGS testing in patients with suspected myeloid malignancy: Bekim Sadikovic, PhD, DABMG, FACMG, Professor, Research Chair, and Program Head, Western University and London Health Sciences, Ontario, Canada, **13:20–13:50 PT**

Comparative performance evaluation of the GeneStrat NGS™ liquid biopsy test for the detection of copy number amplifications, fusions/exon skipping, somatic single nucleotide variants, and indels: Gary Pestano, PhD, Chief Development Officer, NYS CLEP Laboratory Director, Biodesix Inc., Boulder, Colorado, **13:50–14:10 PT**

Q&A: 14:10–14:20 PT

Part 2: Clinical oncology research

Genomic instability metric (GIM) for HRD assessment: Dr. Elaine Wong-Ho, Sr. Product Manager, Oncology, Thermo Fisher Scientific, **14:20–14:35 PT**

Q&A: 14:35–14:40

Genexus System demonstration with live Q&A: Andrew Hutchison, Director, Instruments, Thermo Fisher Scientific, **14:40–14:55 PT**

Register at labroots.com/ms/virtual-event/oncomineworld-2023